The 4506.T stock plunged 22.05% in after-hours trading on 04 Mar 2026, falling to JPY 1,887.50 on the JPX after a heavy sell-off that pushed volume to 16,366,000.00 shares. The drop followed a sharp intraday reversal from a previous close of JPY 2,421.50 and erased the 50-day momentum. Market participants cited sector weakness and profit-taking after recent gains, leaving immediate technical support near JPY 1,851.00 and a crowded order book at the 200-day average of JPY 1,749.82.

4506.T stock: intraday move, volume and price metrics

The first key fact is the scale of the move: price JPY 1,887.50, change -534.00, change % -22.05%, volume 16,366,000.00. This is relative volume of roughly 3.16 times average, signaling forced selling and stop runs.

Trading range details matter for immediate support and resistance. Day low was JPY 1,851.00, day high JPY 1,945.50, 50-day average JPY 2,449.48, 200-day average JPY 1,749.82. Those levels frame near-term trade decisions on JPX.

4506.T stock: fundamentals and valuation snapshot

Sumitomo Pharma (4506.T) trades at PE 5.03 with EPS JPY 389.45 and market cap JPY 778,289,489,907.00, putting valuation well below the Healthcare sector average PE 24.32. Low PE suggests value but can reflect cyclical earnings or risk factors.

Key ratios include PB 2.69, EV/EBITDA 7.15, debt/equity 0.90 and interest coverage 3.27. The company posts strong margins: net margin 24.28% and ROE 48.92%, which support a constructive medium-term view despite the sell-off.

4506.T stock: technicals and trading signals

Technical indicators paint an oversold short-term picture: RSI 37.82, CCI -132.45, and MACD histogram at -51.54. Bollinger lower band sits near JPY 1,852.18, close to observed intraday lows, indicating compressed downside.

Important technical levels are support JPY 1,850.00, resistance JPY 2,449.48 (50-day MA) and a longer-term ceiling near the year high JPY 3,288.00. Short-term momentum favors sellers but mean-reversion traders will watch volume and VWAP tests.

4506.T stock: sector context and market drivers

Sumitomo Pharma operates in Healthcare on the JPX where the sector PE averages 24.32. The stock’s low PE and high ROE contrast with peers and reflect a mix of legacy pharmaceuticals, recent R&D spends, and partnerships such as with Roivant.

Macro and sector flows matter: recent Japan market weakness hit defensives too, and healthcare traded down with the Nikkei, amplifying 4506.T volatility. Watch regulatory news, trial updates, or licensing headlines for directional catalysts.

4506.T stock: Meyka AI grade, analyst context and price targets

Meyka AI rates 4506.T with a score out of 100: 75.57 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects monthly JPY 2,553.62 and quarterly JPY 2,132.41. Versus the current JPY 1,887.50, the monthly forecast implies upside 35.29% and the quarterly implies upside 12.98%. Forecasts are model-based projections and not guarantees.

4506.T stock: risks, catalysts and trade ideas

Primary risks include R&D setbacks, regulatory outcomes, and a tightening interest cost if debt levels rise; interest coverage is 3.27, so earnings shocks could pressure credit metrics.

Potential catalysts are licensing deals, positive trial readouts, and sector rotation back into healthcare. Tactical ideas: consider a staged entry near JPY 1,850.00 support with a stop below JPY 1,750.00, and use profit targets at JPY 2,450.00 and JPY 3,200.00 for multi-month holds.

Final Thoughts

4506.T stock fell sharply after hours on 04 Mar 2026, dropping to JPY 1,887.50 on the JPX and trading on 16,366,000.00 shares, a clear top-losers session move. Valuation remains low relative to the Healthcare sector, with PE 5.03 and robust margins supporting the stock’s case for recovery. Meyka AI’s forecast model projects a monthly target of JPY 2,553.62, implying 35.29% upside versus the current price, but that projection is model-based and not a guarantee. Near-term traders should respect support at JPY 1,851.00 and the 200-day average JPY 1,749.82; longer-term investors should monitor clinical and licensing catalysts. We use quantitative signals, sector comparisons, and analyst context to frame risk-managed entries and price targets. For live updates see our Meyka stock page and read market coverage on recent headlines below.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.